ArticleTargeted oncology2024

A Novel Prognostic Model Using Pan-Immune-Inflammation Value and Programmed Death Ligand 1 in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors: A Retrospective Multicenter Analysis.

Ming-Yu Lien et al.PubMed ↗Publisher ↗

No numbers read from the abstract.